ADALIMUMAB IN PALMOPLANTAR PUSTULOSIS

1S Cortes de Miguel, 2S Belda-Rustarazo, 3C García-Fernández, 3CM Valencia-Soto, 2S Portillo-Haro*. 1Hospital La Inmaculada-Area De Gestión Sanitaria Norte De Almeria, Pharmacy, Huércal-Overa, Spain; 2Hospital Universitario Clínico San Cecilio, Pharmacy, Granada, Spain; 3Hospital Universitario Marqués De Valdecilla, Pharmacy, Santander, Spain

Background and importance Palmoplantar pustulosis (PPP) is a chronic disorder marked by the appearance of recurrent eruptions of fluid filled pustules or blisters on the hands and feet. Its aetiology is unknown and its relationship with psoriasis continues to be controversial. No standardised guidelines are available for treatment. Firstline therapeutic options for PPP include topical corticosteroids, an oral retinoid and photochemotherapy. Patients who do not respond sufficiently to firstline treatment may benefit from combination therapy with an oral retinoid and PUVA or from immunosuppressive therapy. In severe recalcitrant disease, there is some evidence that biologic treatments, psoriasis area severity index (PASI) and dermatology life quality index (DLQI), initial and late, and also increases in dosage. Efficacy was assessed by the per cent reduction in PASI and the DLQI score. The data were obtained from the dispensing registry of outpatients and the medical history.

Results Forty-four patients were included, 48% were men. The initial average value for PASI was 6.36 (SD 3.43) and for DLQI 8.43 (SD 5.81). Secukinumab was the firstline biological treatment in 88.64% of cases, seconline in 45.45% and thirdline in 4.54%. In 86.36% of patients, treatment started with the reduced 150 mg monthly schedule and in 11.36% started with the 300 mg monthly schedule; 26.4% (6 patients) of patients required a dose increase to 300 mg per month. The percentage of patients with reduced PASI was 43.9% obtained a DLQI after the start of treatment of 0 and 45.24% for PASI 75/90/100, respectively:

<table>
<thead>
<tr>
<th>Initial PASI</th>
<th>PASI 75</th>
<th>PASI 90</th>
<th>PASI 100</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.36 (SD 3.43)</td>
<td>43.9%</td>
<td>43.9%</td>
<td>45.24%</td>
</tr>
</tbody>
</table>

Conclusion and relevance Secukinumab, an anti-interleukin 17 (anti-IL-17) drug, has proved to be effective in the treatment of psoriasis at its recommended dose of 300 mg at weeks 0, 1, 2, 3 and 4, and then monthly during the maintenance phase, according to the data sheet.

AIM and objectives To evaluate the efficacy of a reduced monthly dose of 150 mg in patients with moderate–severe psoriasis.

Material and methods A retrospective observational study was conducted including patients treated with seukinumab until March 2019. The variables recorded were sex, previous biological treatments, psoriasis area severity index (PASI) and dermatology life quality index (DLQI), initial and late, and also increases in dosage. Efficacy was assessed by the per cent reduction in PASI and the DLQI score. The data were obtained from the dispensing registry of outpatients and the medical history.

Results Forty-four patients were included, 48% were men. The initial average value for PASI was 6.36 (SD 3.43) and for DLQI 8.43 (SD 5.81). Secukinumab was the firstline biological treatment in 88.64% of cases, seconline in 45.45% and thirdline in 4.54%. In 86.36% of patients, treatment started with the reduced 150 mg monthly schedule and in 11.36% started with the 300 mg monthly schedule; 26.4% (6 patients) of patients required a dose increase to 300 mg per month. The percentage of patients with reduced PASI was 43.9% obtained a DLQI after the start of treatment of 0–1.

Conclusion and relevance The reduced seukinumab regimen of 150 mg monthly both in patients who used it as a firstline biological treatment or after failure with previous treatments, proved to be an effective alternative for moderate–severe psoriasis but long term studies are needed to confirm the effectiveness of dose reduction.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.